Form 4: Barinthus Biotherapeutics CFO Acquires 160,000 Share Options
SEC Form 4 Filing
Gemma Brown, CFO of Barinthus Biotherapeutics, reports the acquisition of 160,000 share options exercisable over the next ten years.
Summary
- Gemma Brown, the Chief Financial Officer of Barinthus Biotherapeutics plc, filed a Form 4 with the SEC.
- The form reports a transaction on February 3, 2025, where Ms. Brown acquired 160,000 share options.
- These options have an exercise price of $1.
- The options vest in three equal annual installments, starting February 3, 2026.
- The options expire on February 3, 2035.
- The ordinary shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one ordinary share.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates the CFO's increased stake in the company.
Positives
- The acquisition of share options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
This type of SEC filing is standard practice for reporting changes in beneficial ownership by company insiders. It's common for executives to receive stock options as part of their compensation packages, aligning their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives.
- The vesting schedule of three equal annual installments is a typical arrangement.
- The ten-year expiration period is also standard practice.
Stakeholder Impact
- The granting of stock options to the CFO aligns her interests with those of the shareholders, potentially incentivizing her to make decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of transaction: CFO acquired 160,000 share options. |
| 02/03/2026 | First vesting date for the share options. |
| 02/03/2035 | Expiration date of the share options. |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.